Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,167
archived clinical trials in
Liver Cancer

Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
A Phase II Study Of rhuMAb VEGF (BEVACIZUMAB) In Patients With Hepatocellular Carcinoma Receiving Chemoembolization
Status: Enrolling
Updated:  2/17/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
A Phase II Study Of rhuMAb VEGF (BEVACIZUMAB) In Patients With Hepatocellular Carcinoma Receiving Chemoembolization
Status: Enrolling
Updated: 2/17/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  2/18/2016
Mount Sinai Hospital
mi
from
New York, NY
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 2/18/2016
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  2/18/2016
Kenmar Research Group
mi
from
Los Angeles, CA
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 2/18/2016
Kenmar Research Group
mi
from
Los Angeles, CA
Click here to add this to my saved trials
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  2/18/2016
Georgetown-Lombardi Cancer Center
mi
from
Washington DC,
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 2/18/2016
Georgetown-Lombardi Cancer Center
mi
from
Washington DC,
Click here to add this to my saved trials
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  2/18/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 2/18/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  2/18/2016
Kurume University Hospital
mi
from
Kurume-shi,
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 2/18/2016
Kurume University Hospital
mi
from
Kurume-shi,
Click here to add this to my saved trials
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
A Phase II Study of TRC105 in Patients With Hepatocellular Carcinoma (HCC) Who Have Progressed on Sorafenib
Status: Enrolling
Updated:  2/18/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
A Phase II Study of TRC105 in Patients With Hepatocellular Carcinoma (HCC) Who Have Progressed on Sorafenib
Status: Enrolling
Updated: 2/18/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
Status: Enrolling
Updated:  2/18/2016
University of Texas Medical Branch at Galveston
mi
from
Galveston, TX
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
Status: Enrolling
Updated: 2/18/2016
University of Texas Medical Branch at Galveston
mi
from
Galveston, TX
Click here to add this to my saved trials
Storage of Bile From Routine Procedures to Study Risk Factors
A Prospective Study of Human Bile and Molecular Predictors of Biliary Malignancy Risk
Status: Enrolling
Updated:  2/22/2016
Indiana University Hospital
mi
from
Indianapolis, IN
Storage of Bile From Routine Procedures to Study Risk Factors
A Prospective Study of Human Bile and Molecular Predictors of Biliary Malignancy Risk
Status: Enrolling
Updated: 2/22/2016
Indiana University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Howard University Cancer Center
mi
from
Washington,
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Howard University Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Medical College of Georgia Cancer Center
mi
from
Augusta, GA
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Medical College of Georgia Cancer Center
mi
from
Augusta, GA
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Burlington County
mi
from
Mount Holly, NJ
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Burlington County
mi
from
Mount Holly, NJ
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Hematology Oncology Associates of Central New York, PC - Northeast Center
mi
from
East Syracuse, NY
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Hematology Oncology Associates of Central New York, PC - Northeast Center
mi
from
East Syracuse, NY
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Don Monti Comprehensive Cancer Center at North Shore University Hospital
mi
from
Manhasset, NY
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Don Monti Comprehensive Cancer Center at North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
CCOP - Main Line Health
mi
from
Wynnewood, PA
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
CCOP - Main Line Health
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Nashville General Hospital at Meharry
mi
from
Nashville, TN
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Nashville General Hospital at Meharry
mi
from
Nashville, TN
Click here to add this to my saved trials
ABT-888 and Temozolomide for Liver Cancer
Phase II Study of ABT-888 and Temozolomide in Patients With Advanced Hepatocellular Carcinoma (HCC) Progressing Following Sorafenib Treatment or Intolerant to Sorafenib
Status: Enrolling
Updated:  3/2/2016
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington,
ABT-888 and Temozolomide for Liver Cancer
Phase II Study of ABT-888 and Temozolomide in Patients With Advanced Hepatocellular Carcinoma (HCC) Progressing Following Sorafenib Treatment or Intolerant to Sorafenib
Status: Enrolling
Updated: 3/2/2016
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
A Phase 1 Study of ADI PEG 20 Plus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  3/2/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
A Phase 1 Study of ADI PEG 20 Plus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 3/2/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
A Phase 1 Study of ADI PEG 20 Plus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  3/2/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
A Phase 1 Study of ADI PEG 20 Plus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 3/2/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions
Status: Enrolling
Updated:  3/4/2016
UCLA
mi
from
Los Angeles, CA
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions
Status: Enrolling
Updated: 3/4/2016
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions
Status: Enrolling
Updated:  3/4/2016
Montefiore Medical Center
mi
from
Bronx, NY
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions
Status: Enrolling
Updated: 3/4/2016
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions
Status: Enrolling
Updated:  3/4/2016
Cleveland Clinic Hospital
mi
from
Cleveland, OH
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions
Status: Enrolling
Updated: 3/4/2016
Cleveland Clinic Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions
Status: Enrolling
Updated:  3/4/2016
Rhode Island Hospital
mi
from
Providence, RI
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions
Status: Enrolling
Updated: 3/4/2016
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Phase II Single Arm Study of Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  3/8/2016
Univ. of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Phase II Single Arm Study of Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 3/8/2016
Univ. of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Phase II Single Arm Study of Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  3/8/2016
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Phase II Single Arm Study of Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 3/8/2016
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Phase II Single Arm Study of Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  3/8/2016
Moffitt Cancer Center
mi
from
Tampa, FL
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Phase II Single Arm Study of Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 3/8/2016
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
Pilot Study of Sequential Hepatic Radioembolization and Systemic Ipilimumab in Patients With Uveal Melanoma Metastatic to Liver
Status: Enrolling
Updated:  3/9/2016
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
Pilot Study of Sequential Hepatic Radioembolization and Systemic Ipilimumab in Patients With Uveal Melanoma Metastatic to Liver
Status: Enrolling
Updated: 3/9/2016
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
Decatur Memorial Hospital
mi
from
Decatur, IL
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
Ingalls Memorial Hospital
mi
from
Harvey, IL
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
Joliet Oncology-Hematology Associates Limited
mi
from
Joliet, IL
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
Joliet Oncology-Hematology Associates Limited
mi
from
Joliet, IL
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
Loyola University Medical Center
mi
from
Maywood, IL
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance
Impact of C-arm CT in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transhepatic Arterial Chemoembolization (TACE): Optimal Imaging Guidance
Status: Enrolling
Updated:  3/10/2016
Stanford University School of Medicine
mi
from
Stanford, CA
Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance
Impact of C-arm CT in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transhepatic Arterial Chemoembolization (TACE): Optimal Imaging Guidance
Status: Enrolling
Updated: 3/10/2016
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers
Status: Enrolling
Updated:  3/15/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers
Status: Enrolling
Updated: 3/15/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers
Status: Enrolling
Updated:  3/15/2016
MedStar Georgetown University Hospital
mi
from
Washington,
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers
Status: Enrolling
Updated: 3/15/2016
MedStar Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers
Status: Enrolling
Updated:  3/15/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers
Status: Enrolling
Updated: 3/15/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers
Status: Enrolling
Updated:  3/15/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers
Status: Enrolling
Updated: 3/15/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers
Status: Enrolling
Updated:  3/15/2016
Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers
Status: Enrolling
Updated: 3/15/2016
Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers
Status: Enrolling
Updated:  3/15/2016
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers
Status: Enrolling
Updated: 3/15/2016
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials